Sep 27, 2016

AbbVie Repeats as a Working Mother “100 Best Company”

For the fourth consecutive year, AbbVie has made Working Mother magazine’s list of “100 Best Companies.

Sep 20, 2016

14 Ways Your Donation Helps Real People

When you donate to a worthy cause, you want to know exactly how that contribution helps real people.
Sep 16, 2016

What We’re Learning from Alzheimer’s Research and How Biomarkers May Help

Hope and expectation have never met more frequently with disappointment in clinical trial research for Alzheimer’s disease. But the question is, why? 

Sep 08, 2016

AbbVie Leads Industry in Dow Jones Sustainability World Index

AbbVie is the industry leader in Dow Jones Sustainability World Index with the highest score of 34 biotechnology companies.
Sep 02, 2016

The Surprising Reasons People Don’t Do What the Doctor Ordered

Half of all people with chronic diseases don’t take their medications as directed. Finding out why is only half the battle.

Aug 05, 2016

World-Renowned Soccer Star Tackles a New Challenge

For soccer star Brandi Chastain, having a game plan was second nature, until last year when she had to tackle a different type of plan.

Jul 29, 2016

Second Quarter 2016 Financial Results

Double-digit revenue and adjusted EPS growth for the 6th consecutive quarter
Jul 25, 2016

How a World Free from Viral Hepatitis is Possible

On the heels of World Hepatitis Day, advocacy leader Raquel Peck reflects on what viral hepatitis elimination means, the significance of 2030 and her Haribo candy love. 



Sep 26, 2016

AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress

NORTH CHICAGO, Ill., Sept. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine risankizumab (formerly BI 655066), an IL-23 inhibitor, will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), September 28 - October 2, in Vienna, Austria. These presentations build upon AbbVie's continued scientific leadership in serious dermatological conditions including psoriasis, psoriatic arthritis and hidradenitis suppurativa.

Sep 26, 2016

AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma

NORTH CHICAGO, Ill., Sept. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ibrutinib (IMBRUVICA®) to treat patients with marginal zone lymphoma (MZL). MZL is a slow-growing form of non-Hodgkin's lymphoma. The Company's sNDA submission is based on data from a multi-center, open-label Phase II PCYC-1121-CA trial assessing ibrutinib as a single-agent treatment for MZL. If approved, MZL will be the fifth unique type of blood cancer indication for IMBRUVICA. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.

Sep 23, 2016

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

NORTH CHICAGO, Ill., Sept. 23, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) treatment. In the Phase 3b GARNET study, 98 percent (n=160/163) of previously untreated patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis achieved sustained virologic response rates at 12 weeks post-treatment (SVR12).1 These data were presented today at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure, in Paris, France and included in the newly published 'EASL Recommendations on Treatment of Hepatitis C.' VIEKIRAX + EXVIERA is currently approved in the European Union for GT1b patients without cirrhosis or with compensated cirrhosis for 12 weeks.